Ukwelashwa Okusha Kwabantu Abadala Abane-Active Psoriatic Arthritis

I-AbbVie, inkampani yomhlaba wonke esekwe ocwaningweni lwe-biopharmaceutical, imemezele ukuthi i-Health Canada igunyaze i-SKYRIZI® (risankizumab), yokwelapha iziguli ezikhulile ezine-psoriatic arthritis esebenzayo. Ku-PSA, i-SKYRIZI ingasetshenziswa iyodwa noma ihlanganiswe nomuthi ovamile ongewona we-biologic-modifying antirheumatic drug (cDMARD) (isb, i-methotrexate).   

“I-SKYRIZI yokuthola i-Notice of Compliance yokwelashwa kwe-apsoriatic arthritis esebenzayo kunikeza ithemba elengeziwe ezigulini. Imiphumela evela ohlelweni lokuhlolwa komtholampilo lweSigaba sesi-3 ibonisa ukuthuthukiswa kwezimpawu nezimpawu ezihlobene nalesi sifo, "kusho uDkt Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.

"Kwa-AbbVie, silwela ukuguqula izinga lokunakekelwa kwabantu abangenawo amandla omzimba, futhi sijabule ngokugunyazwa yi-Health Canada ye-SKYRIZI yokwelapha abantu abadala abane-psoriatic arthritis esebenzayo," kusho u-Tracey Ramsay, iPhini likaMongameli kanye noMphathi Jikelele, i-AbbVie Canada.  

Lesi yinkomba yesibili ye-SKYRIZI eCanada. Ngo-Ephreli 2019, i-Health Canada yagunyaza i-SKYRIZI yokwelashwa kweziguli ezikhulile ezine-plaque psoriasis emaphakathi neziqinile ezidinga ukwelashwa kwe-systemic noma i-phototherapy.